Evolent Health Inc (EVH) concluded trading on Thursday at a closing price of $11.18, with 3.39 million shares of worth about $37.85 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -50.31% during that period and on December 19, 2024 the price saw a gain of about 4.39%. Currently the company’s common shares owned by public are about 115.01M shares, out of which, 111.83M shares are available for trading.
Stock saw a price change of -1.93% in past 5 days and over the past one month there was a price change of -6.44%. Year-to-date (YTD), EVH shares are showing a performance of -66.15% which decreased to -63.87% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $10.53 but also hit the highest price of $35.00 during that period. The average intraday trading volume for Evolent Health Inc shares is 2.57 million. The stock is currently trading -4.27% below its 20-day simple moving average (SMA20), while that difference is down -35.16% for SMA50 and it goes to -53.73% lower than SMA200.
Evolent Health Inc (NYSE: EVH) currently have 115.01M outstanding shares and institutions hold larger chunk of about 110.57% of that.
The stock has a current market capitalization of $1.30B and its 3Y-monthly beta is at 1.46. It has posted earnings per share of -$0.91 in the same period. It has Quick Ratio of 1.04 while making debt-to-equity ratio of 0.79. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for EVH, volatility over the week remained 5.97% while standing at 5.84% over the month.
Stock’s fiscal year EPS is expected to drop by -28.91% while it is estimated to increase by 55.48% in next year. EPS is likely to grow at an annualized rate of 30.00% for next 5-years, compared to annual growth of -13.43% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BTIG Research on December 03, 2024 offering a Buy rating for the stock and assigned a target price range of between $36 and $29 to it. Coverage by Stephens stated Evolent Health Inc (EVH) stock as an Equal-weight in their note to investors on November 08, 2024, suggesting a price target of $16 for the stock. On October 11, 2024, KeyBanc Capital Markets Initiated their recommendations, while on August 09, 2024, Truist Upgrade their ratings for the stock with a price target of $33. Stock get a Buy rating from Citigroup on April 22, 2024.
